Product image of Linagliptin/Metformin Stada (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptin/Metformin Stada

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptin/Metformin Stada (Metformin Hydrochloride, Linagliptin)

Linagliptin/Metformin, the active ingredient in Linagliptin/Metformin Stada, is a DPP‑4 inhibitor; Biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, improving blood glucose control when combined with diet, exercise, and other antidiabetic agents as needed.

GNH India supplies Linagliptin/Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin/Metformin is used in the treatment of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

  • Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise.
  • Postprandial hyperglycemia: reduces post‑meal glucose excursions by enhancing insulin secretion.
  • Combination therapy: can be combined with insulin or other oral antidiabetics to achieve target HbA1c.
  • Metabolic syndrome with elevated glucose: assists in lowering fasting plasma glucose levels.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones, thereby increasing glucose‑dependent insulin secretion and suppressing glucagon release. Metformin hydrochloride primarily reduces hepatic gluconeogenesis, enhances peripheral insulin sensitivity, and decreases intestinal glucose absorption. The fixed‑dose combination therefore provides dual action on both insulin secretion and insulin resistance to improve blood glucose levels in patients with type 2 diabetes.

Side Effects

Linagliptin/Metformin may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: loose stools, usually transient.
  • Headache: mild cranial discomfort.
  • Upper respiratory tract infection: symptoms such as sore throat or runny nose.
  • Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic disturbance.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Allergic reactions: rash, angioedema, or anaphylaxis.

Precautions & Warnings

Before prescribing Linagliptin/Metformin, clinicians should consider several safety precautions.

  • Renal function: assess creatinine clearance and avoid use in severe renal impairment.
  • Hepatic function: monitor liver enzymes in patients with existing liver disease.
  • Lactic acidosis risk: discontinue if signs of metabolic acidosis appear.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
  • Concomitant sulfonylureas or insulin: monitor for hypoglycemia and adjust dose accordingly.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Avoid Interactions

Linagliptin/Metformin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
  • Rifampicin: induces metabolism, reducing linagliptin levels.
  • Cimetidine: impairs metformin renal clearance, raising risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

  • NSAIDs (e.g., ibuprofen): may affect renal function and metformin elimination.
  • ACE inhibitors or ARBs: combined use can increase risk of renal impairment.
  • Thyroid hormones: may alter glycemic control, requiring dose adjustment.

Frequently Asked Questions

Linagliptin/Metformin Stada is indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose levels by combining the actions of a DPP‑4 inhibitor and a biguanide, and is used when diet, exercise, and other monotherapy agents are insufficient to achieve glycemic targets.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in higher levels of endogenous incretin hormones. These hormones increase insulin secretion in a glucose‑dependent manner and reduce glucagon release, thereby contributing to lower post‑prandial blood glucose.

The specific dose of Linagliptin/Metformin is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety of Linagliptin/Metformin in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefits outweigh the potential risks to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, the fixed‑dose combination offers dual mechanisms—enhancing insulin secretion via DPP‑4 inhibition and improving insulin sensitivity through metformin. This can provide better glycemic control than either component alone and may reduce the pill burden versus taking two separate tablets.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain product stability.

Linagliptin/Metformin is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious risks include lactic acidosis, which is a rare but life‑threatening condition, and severe hypoglycemia, especially when used with insulin or sulfonylureas. Acute pancreatitis and serious allergic reactions such as anaphylaxis are also rare but require immediate medical attention.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with certain metabolic disorders that predispose to acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT